GlassScriptPhysician profile
Hai N Nguyen
NPI 1235295551
$4,924.31
in general payments reported to CMS, 2019-2025
30 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $1,071 · 2021: $980 · 2022: $928 · 2023: $464 · 2024: $531 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $922.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $746.11 | 2021-2025 | |
| Eko Health, INC. | $500.00 | 2020 | |
| Novo Nordisk INC | $394.80 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $310.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.62 | 2020-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $238.42 | 2023-2025 | |
| Allergan, INC. | $221.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $167.90 | 2019-2025 | Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $147.37 | 2019-2025 | Breztri, Flumist Quadrivalent, Airsupra |
| Vbi Vaccine (Delaware) INC. | $146.22 | 2022-2023 | Prehevbrio |
| Corcept Therapeutics | $140.15 | 2024-2025 | Korlym |
| Aerin Medical INC. | $101.20 | 2019 | |
| Amarin Pharma, INC. | $94.86 | 2019-2020 | |
| Abbott Laboratories | $81.25 | 2022-2023 | Freestyle Libre |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $60.05 | 2022-2023 | Gvoke Hypopen |
| Mannkind Corporation | $59.40 | 2022 | |
| Vanda Pharmaceuticals INC. | $58.13 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $50.41 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $42.67 | 2025 | Natroba, Spinosad |
| Scilex Pharmaceuticals INC. | $36.63 | 2022 | |
| Currax Pharmaceuticals LLC | $32.25 | 2021-2023 | Onzetra Xsail, Contrave |
| Biohaven Pharmaceuticals, INC. | $27.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.05 | 2022 | |
| Boston Scientific Corporation | $17.38 | 2022 | |
| Glaxosmithkline, LLC. | $16.79 | 2019 | |
| Genentech USA, INC. | $13.97 | 2019 | |
| Gilead Sciences, INC. | $13.47 | 2019 | |
| Horizon Therapeutics Plc | $11.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hai Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.